HomeMarket NewsRoche/Genentech MS Drug Faces FDA Setback

Roche/Genentech MS Drug Faces FDA Setback

Actionable Trade Ideas

always free

Multiple sclerosis (multiple sclerosis) a disease that affects the nervous system, written on wooden blocks, health concept, rare disease detection and treatment, lettering on puzzle pieces

Andrzej Rostek

The FDA has slammed the brakes on Roche’s (OTCQX:RHHBY) Genentech subsidiary’s development program for the drug fenebrutinib, a potential treatment for multiple sclerosis.

Genentech revealed that the FDA took action after two cases of elevated liver enzymes and bilirubin, which indicated drug-induced liver injury, occurred during a Phase 3 study of the drug in relapsing MS. The elevated levels returned to normal after the drug was withdrawn.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.